Head-to-head evidence
Loxapine (Adasuve) vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: June 2028 · NCT05603104 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Quetiapine (Seroquel)'s landscape